Novel approach for treating inflammatory disorders
AssigneeSecarna Pharmaceuticals GmbH & Co. KG
InventorsFrank JASCHINSKI, Ksenija SCHIRDUAN, Sven MICHEL
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel approach for treating inflammatory disorders and other diseases, which is based on targeting ROR gamma t mRNA. The invention is directed to oligonucleotides comprising 10 to 22 modified or unmodified nucleotides complementary to specifically selected regions of the RORC, transcript variant 2 mRNA (RORC2), which codes for the ROR gamma t protein.
Claims19
An oligonucleotide consisting of from 15 to 21 nucleotides, wherein the sequence of said oligonucleotide comprises the sequence GTGTTC, which is complementary to positions 146 to 151 of the RORC2 nucleic acid coding sequence of SEQ ID NO. 1, and wherein one or more nucleotide(s) of the oligonucleotide is/are optionally modified.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.